<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chlorambucil: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chlorambucil: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Chlorambucil: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9240" href="/d/html/9240.html" rel="external">see "Chlorambucil: Drug information"</a> and <a class="drug drug_patient" data-topicid="11323" href="/d/html/11323.html" rel="external">see "Chlorambucil: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708649"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Chlorambucil can severely suppress bone marrow function.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Adverse effects:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Chlorambucil is a carcinogen in humans. Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F149339"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Leukeran</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866287"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Leukeran</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1046195"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Alkylating Agent</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)</span></li></ul></div>
<div class="block dop drugH1Div" id="F149362"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> For oncologic uses, dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma:</b> Limited data available: Infants ≥7 months, Children, and Adolescents: ChlVPP regimen: Oral: 6 mg/<b>m<sup>2</sup></b>/day on days 1 to 14 of a 28-day cycle for 6 to 10 cycles in combination with vinblastine, procarbazine, and prednisolone (Atra 2002; Capra 2007; Hall 2007; Stoneham 2007)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5d66d434-0c48-451f-8b7c-ac362bd8a039">Nephrotic syndrome; frequently relapsing steroid-sensitive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nephrotic syndrome; frequently relapsing steroid-sensitive:</b> Limited data available: Children and Adolescents: Oral: 0.1 to 0.2 mg/kg/day once daily for 8 weeks (maximum cumulative dose: 11.2 mg/kg) (Baluarte 1978; Hodson 2010; KDIGO 2012); <b>Note:</b> Chlorambucil is not a preferred agent due to a higher incidence of adverse effects with no greater efficacy (Gipson 2009).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult:</p>
<p style="text-indent:-2em;margin-left:6em;">Skin reactions: Discontinue treatment</p>
<p style="text-indent:-2em;margin-left:6em;">Hematologic:</p>
<p style="text-indent:-2em;margin-left:8em;">WBC or platelets below normal: Reduce dose</p>
<p style="text-indent:-2em;margin-left:8em;">Severely depressed WBC or platelet counts: Discontinue</p>
<p style="text-indent:-2em;margin-left:8em;">Persistently low neutrophil or platelet counts or peripheral lymphocytosis: May be suggestive of bone marrow infiltration; if infiltration confirmed, do not exceed 0.1 mg/kg/day in adults</p>
<p style="text-indent:-2em;margin-left:6em;">Concurrent or within 4 weeks (before or after) of chemotherapy/radiotherapy: Initiate treatment cautiously; reduce dose; monitor closely.</p></div>
<div class="block dorp drugH1Div" id="F51084652"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; however, based on experience in adult patients, renal elimination of unchanged chlorambucil and active metabolite (phenylacetic acid mustard) is minimal and renal impairment is not likely to affect elimination.</p></div>
<div class="block dohp drugH1Div" id="F51259936"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Chlorambucil undergoes extensive hepatic metabolism. Although dosage reduction should be considered in patients with hepatic impairment, there are no dosage adjustments provided in the manufacturer's labeling (data is insufficient).</p></div>
<div class="block doa drugH1Div" id="F149343"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9240" href="/d/html/9240.html" rel="external">see "Chlorambucil: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Reduce initial dose if full-dose radiation or myelotoxic drugs have been administered within the last month. With bone marrow lymphocytic infiltration involvement (in chronic lymphocytic leukemia [CLL], Hodgkin lymphoma, or non-Hodgkin lymphoma [NHL]), the manufacturer recommends a maximum dose of 0.1 mg/kg/day; while short treatment courses are preferred, if maintenance therapy is required, the manufacturer recommends a maximum dose of 0.1 mg/kg/day.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c2daff1-da41-460d-97f5-616d486189ba">Chronic lymphocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic lymphocytic leukemia in previously untreated patients (off-label dosing): </i>0.4 mg/kg day 1 every 2 weeks; if tolerated may increase by 0.1 mg/kg with each treatment course to a maximum dose of 0.8 mg/kg and maximum of 24 cycles (Eichhorst 2009) <b>or</b> 0.5 mg/kg on days 1 and 15 every 28 days for 6 cycles (Goede 2014) <b>or </b>30 mg/m<sup>2</sup> day 1 every 2 weeks (in combination with prednisone) (Raphael 1991) <b>or</b> 40 mg/m<sup>2</sup> day 1 every 4 weeks until disease progression or complete remission or response plateau for up to a maximum of 12 cycles (Rai 2000).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic lymphocytic leukemia in previously untreated patients (off-label combinations):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Chlorambucil-obinutuzumab: </i>0.5 mg/kg on days 1 and 15 every 28 days for 6 cycles (Goede 2014).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Chlorambucil-ofatumumab: </i>10 mg/m<sup>2</sup> once daily for 7 days (days 1 to 7) every 28 days for a minimum of 3 cycles and up to 12 cycles or best response (clinical response that did not improve after 3 additional cycles); if necessary, reduce dose to 7.5 mg/m<sup>2</sup>/day and then to 5 mg/m<sup>2</sup>/day for hematologic toxicity (Hillmen 2015).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Chlorambucil-rituximab: </i>10 mg/m<sup>2</sup> once daily for 7 days (days 1 to 7) every 28 days for 6 to 12 cycles (Hillmen 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer’s labeling:</i> 0.1 mg/kg/day for 3 to 6 weeks <b>or</b> 0.4 mg/kg pulsed doses administered intermittently, biweekly, or monthly (increased by 0.1 mg/kg/dose until response/toxicity observed).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma:</b>
<b>Oral</b>
<b>:</b>
<i>ChlVPP regimen:</i> 6 mg/m<sup>2</sup> once daily (maximum 10 mg/day) on days 1 to 14 every 28 days (in combination with vinblastine, procarbazine, and prednisolone) until complete remission plus 2 cycles (Selby 1990) <b>or</b> 6 mg/m<sup>2</sup> once daily on days 1 to 14 every 28 days (in combination with vinblastine, procarbazine, and prednisone) for 6 cycles (Vose 1991).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a12d60b7-da1c-4164-abc4-8a98c9ddfba0">Idiopathic membranous nephropathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Idiopathic membranous nephropathy (alternative agent) (off-label use): Oral:</b> 0.15 to 0.2 mg/kg/day during months 2, 4, and 6 (alternating with prednisolone/methylprednisolone during months 1, 3, and 5) (Howman 2013; KDIGO 2012). <b>Note:</b> Due to potential adverse events, other agents may be preferred over chlorambucil.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b6ee3d50-e711-467f-ab9b-8a2d03573f1f">Necrobiotic xanthogranuloma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Necrobiotic xanthogranuloma (off-label use; based on limited data): Oral:</b> 2 to 4 mg once daily either with or without systemic corticosteroids (Finan 1986; Hilal 2018; Mehregan 1992; Miguel 2017) <b>or</b> 10 mg once daily for 14 days of a 28-day treatment cycle for 8 cycles (Ryan 2012) <b>or</b> 10 mg once daily, reduced to 2 mg once daily (in combination with prednisone) (Wells 2004).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d4c856e-dedc-4b57-9bc3-4eb783e31618">Non-Hodgkin lymphomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphomas:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Follicular lymphoma (off-label dosing):</b> 6 mg/m<sup>2</sup> once daily during weeks 1 to 6, followed 8 weeks later (if response occurred) by 6 mg/m<sup>2 </sup>once daily for 2 weeks of a 4-week cycle for 4 cycles (in combination with rituximab) (Martinelli 2003; Martinelli 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mucosa-associated lymphoid tissue lymphoma (off-label dosing):</b> 6 mg/m<sup>2</sup> once daily during weeks 1 to 6, followed by 6 mg/m<sup>2 </sup>once daily for 2 weeks of a 4-week cycle for up to 4 cycles (in combination with rituximab) (Zucca 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer’s labeling:</i> 0.1 mg/kg/day for 3 to 6 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ebda9a81-6b8d-4064-acf9-5c892f36549f">Waldenström macroglobulinemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Waldenström macroglobulinemia (alternative agent) (off-label use):</b>
<b>Oral:</b> 8 mg/m<sup>2</sup> (6 mg/m<sup>2</sup> in patients &gt;75 years of age) once daily for 10 days every 28 days for up to 12 cycles (Leblond 2013) <b>or</b> 0.1 mg/kg/day (continuously) for at least 6 months (Kyle 2000) <b>or</b> 0.3 mg/kg/day for 7 days every 6 weeks for at least 6 months (Kyle 2000).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991510"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, renal elimination of unchanged chlorambucil and active metabolite (phenylacetic acid mustard) is minimal and renal impairment is not likely to affect elimination. The following adjustments have been recommended:</p>
<p style="text-indent:-2em;margin-left:2em;">Aronoff 2007:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;50 mL/minute: No adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 10 to 50 mL/minute: Administer 75% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis (PD): Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Kintzel 1995: Based on the pharmacokinetics, dosage adjustment is not indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Idiopathic membranous nephropathy (off-label use):</i> Serum creatinine &gt;2 mg/dL: Maximum daily dose: 0.1 mg/kg/day (KDIGO 2012).</p></div>
<div class="block doha drugH1Div" id="F50988881"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Chlorambucil undergoes extensive hepatic metabolism. Although dosage reduction should be considered in patients with hepatic impairment, there are no dosage adjustments provided in the manufacturer's labeling (data is insufficient).</p></div>
<div class="block adr drugH1Div" id="F149306"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Drug fever, peripheral neuropathy</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Allergic skin reaction, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Amenorrhea</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Diarrhea (infrequent), nausea (infrequent), oral mucosa ulcer (infrequent), vomiting (infrequent)</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Azoospermia, cystitis (sterile), infertility</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Anemia, bone marrow depression, bone marrow failure (irreversible), leukemia (secondary), leukopenia, lymphocytopenia, malignant neoplasm (secondary), neutropenia (onset: 3 weeks; recovery: 10 days after last dose), pancytopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Hepatotoxicity, jaundice</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Angioedema, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Interstitial pneumonitis, pulmonary fibrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">1%, postmarketing, and/or case reports: Agitation, ataxia, confusion, erythema multiforme, flaccid paralysis, seizure (focal/generalized), hallucination, muscle twitching, myoclonus, SIADH (syndrome of inappropriate antidiuretic hormone secretion), Stevens-Johnson syndrome, toxic epidermal necrolysis, tremor</p></div>
<div class="block coi drugH1Div" id="F149322"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to chlorambucil or any component of the formulation; hypersensitivity to other alkylating agents (may have cross-hypersensitivity); prior (demonstrated) resistance to chlorambucil</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Use within 4 weeks of a full course of radiation or chemotherapy</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F149303"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: <b>[US Boxed Warning]: <b>Chlorambucil may </b> cause severe bone marrow suppression;</b> neutropenia may be severe. Reduce initial dosage if patient has received myelosuppressive or radiation therapy within the previous 4 weeks, or has a depressed baseline leukocyte or platelet count. Irreversible bone marrow damage may occur with total doses approaching 6.5 mg/kg. Progressive lymphopenia may develop (recovery is generally rapid after discontinuation).</p>
<p style="text-indent:-2em;margin-left:4em;">• Fertility effects: <b>[US Boxed Warning]: <b>Chlorambucil is probably mutagenic and teratogenic in humans. Chlorambucil produces human infertility. </b></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Secondary malignancy: <b>[US Boxed Warning]: Chlorambucil is a human carcinogen;</b> acute myelocytic leukemia and secondary malignancies may be associated with chronic therapy. Duration of treatment and higher cumulative doses are associated with a higher risk for development of leukemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Have been observed with use; patients with a history of nephrotic syndrome and high pulse doses are at higher risk of seizures. Use with caution in patients with a history of seizure disorder or head trauma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin reactions: Rare instances of severe skin reactions (eg, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported; discontinue promptly if skin reaction occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Chlorambucil is primarily metabolized in the liver. Dosage reductions should be considered in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: Avoid administration of live vaccines to immunocompromised patients.</p></div>
<div class="block foc drugH1Div" id="F149314"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Leukeran: 2 mg</p></div>
<div class="block geq drugH1Div" id="F149299"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F149324"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Leukeran Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $666.07</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866288"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Leukeran: 2 mg</p></div>
<div class="block exp drugH1Div" id="F149320"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;">A 2 mg/mL oral suspension may be prepared with tablets. Crush sixty 2 mg tablets in a mortar and reduce to a fine powder. Add small portions of methylcellulose 1% and mix to a uniform paste (total methylcellulose: 30 mL); mix while adding simple syrup in incremental proportions to <b>almost</b> 60 mL; transfer to a graduated cylinder, rinse mortar and pestle with simple syrup, and add quantity of vehicle sufficient to make 60 mL. Transfer contents of graduated cylinder to an amber prescription bottle. Label "shake well", "refrigerate", and "protect from light". Stable for 7 days refrigerated.</p>
<div class="reference">Dressman JB and Poust RI. Stability of Allopurinol and of Five Antineoplastics in Suspension. <i>Am J Hosp Pharm</i>. 1983;40(4):616-618.<span class="pubmed-id">6846371</span></div>
<div class="reference">Nahata MC, Pai VB, and Hipple TF. <i>Pediatric Drug Formulations</i>, 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.</div>
</div>
<div class="block admp drugH1Div" id="F52612398"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered as a single daily dose; preferably on an empty stomach.</p></div>
<div class="block adm drugH1Div" id="F149318"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: May be administered as a single daily dose. </p></div>
<div class="block hazard drugH1Div" id="F49130944"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F149334"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store in refrigerator at 2°C to 8°C (36°F to 46°F).</p></div>
<div class="block usep drugH1Div" id="F53565994"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of chronic lymphocytic leukemia (CLL), Hodgkin's and non-Hodgkin's lymphoma (FDA approved in adults); has also been used in the treatment of nephrotic syndrome (unresponsive to conventional therapy) and Waldenström's macroglobulinemia </p></div>
<div class="block mst drugH1Div" id="F149390"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Chlorambucil may be confused with Chloromycetin</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Leukeran may be confused with Alkeran, leucovorin, Leukine, Myleran</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299014"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F149308"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F13645942"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Absorption is decreased when administered with food. Management: Administer preferably on an empty stomach.</p></div>
<div class="block rep_considerations drugH1Div" id="F49296618"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">
<b>[US Boxed Warning]: Chlorambucil produces human infertility.</b> Chromosomal damage has been documented. Reversible and irreversible sterility (when administered to prepubertal and pubertal males), azoospermia (in adult males), and amenorrhea (in females) have been observed. Fibrosis, vasculitis, and depletion of primordial follicles have been noted on autopsy of the ovaries.</p>
<p style="text-indent:0em;">Women of childbearing potential should avoid becoming pregnant while receiving treatment.</p></div>
<div class="block pri drugH1Div" id="F149325"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Following exposure during the first trimester, case reports have noted adverse renal effects (unilateral agenesis) in the newborn.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>[US Boxed Warning]: </b>
<b>Chlorambucil is probably mutagenic and teratogenic in humans. </b></p></div>
<div class="block mopp drugH1Div" id="F53565975"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver function tests, CBC with differential (weekly, with WBC monitored weekly during the first 3 to 6 weeks of treatment)</p></div>
<div class="block pha drugH1Div" id="F149302"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Chlorambucil is an alkylating agent that interferes with DNA replication and RNA transcription by alkylation and cross-linking the strands of DNA, inducing cellular apoptosis.</p></div>
<div class="block phk drugH1Div" id="F149321"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and complete (&gt;70%) from GI tract; reduced with food</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~0.31 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~99%; primarily to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (extensively); primarily to active metabolite, phenylacetic acid mustard; chlorambucil and phenylacetic acid mustard undergo oxidative degradation</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Chlorambucil: ~1.5 hours; Phenylacetic acid mustard: 1.8 ± 0.4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Chlorambucil: Within 1 hour; Phenylacetic acid mustard: 1.9 ± 0.7 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~20% to 60% within 24 hours, primarily as inactive metabolites, &lt;1% as unchanged drug or phenylacetic acid mustard)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F149326"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Clorambucilo | Leukeran</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Chlorobutin | Leukeran</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Clorambucilo aspen | Leukeran</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Chlorambusil | Leukeran</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Chloraminophene</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Chlorbutin | Leukeran</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Celkeran | Chloramax | Clokeran | Leukeran</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Chlorobutin | Leukeran</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Chlorobutin | Leukeran</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Chlorobutin | Leukeran</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Chlorbutin | Chlorobutin | Leukeran | Loramyl</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Leukeran | Linfoxan</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Leukeran</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007:98.</div>
</li>
<li>
<div class="reference">
                  Atra A, Higgs, E, Capra M, et al. ChlVPP chemotherapy in children with stage IV Hodgkin’s disease: results of the UKCCSG HD 8201 and HD 9201 studies. <i>Br J Hematol</i>. 2002;119:647-651.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-621612">
<a name="621612"></a>Baluarte HJ, Hiner L, Gruskin AB. Chlorambucil Dosage in Frequently Relapsing Nephrotic Syndrome: A Controlled Clinical Trial. <i>J Pediatr</i>. 1978;92(2):295-298.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/621612/pubmed" id="621612" target="_blank">621612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7005681">
<a name="7005681"></a>Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. <i>N Engl J Med</i>. 1981;304(8):441-447. doi:10.1056/NEJM198102193040801<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/7005681/pubmed" id="7005681" target="_blank">7005681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17379506">
<a name="17379506"></a>Capra M, Hewitt M, Radford M, et al. Long-term outcome in children with Hodgkin's lymphoma: the United Kingdom Children's Cancer Study Group HD82 trial. <i>Eur J Cancer</i>. 2007;43(7):1171-1179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/17379506/pubmed" id="17379506" target="_blank">17379506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19605849">
<a name="19605849"></a>Eichhorst BF, Busch R, Stilgenbauer S, et al; German CLL Study Group (GCLLSG). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. <i>Blood</i>. 2009;114(16):3382-3391. doi:10.1182/blood-2009-02-206185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/19605849/pubmed" id="19605849" target="_blank">19605849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3097454">
<a name="3097454"></a>Finan MC, Winkelmann RK. Necrobiotic xanthogranuloma with paraproteinemia. A review of 22 cases. <i>Medicine (Baltimore)</i>. 1986;65(6):376-388. doi:10.1097/00005792-198611000-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/3097454/pubmed" id="3097454" target="_blank">3097454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30328142">
<a name="30328142"></a>Gertz MA. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. <i>Am J Hematol</i>. 2019;94(2):266-276. doi:10.1002/ajh.25292<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/30328142/pubmed" id="30328142" target="_blank">30328142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19651590">
<a name="19651590"></a>Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. <i>Pediatrics</i>. 2009;124(2):747-757.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/19651590/pubmed" id="19651590" target="_blank">19651590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24401022">
<a name="24401022"></a>Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. <i>N Engl J Med</i>. 2014;370(12):1101-1110. doi:10.1056/NEJMoa1313984<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/24401022/pubmed" id="24401022" target="_blank">24401022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol.</i> 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17760808">
<a name="17760808"></a>Hall GW, Katzilakis N, Pinkerton CR, et al. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma – a Children’s Cancer and Leukaemia Group report. <i>Br J Hematol</i>, 2007;138;761-768.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/17760808/pubmed" id="17760808" target="_blank">17760808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29568990">
<a name="29568990"></a>Hilal T, DiCaudo DJ, Connolly SM, Reeder CB. Necrobiotic xanthogranuloma: a 30-year single-center experience. <i>Ann Hematol</i>. 2018;97(8):1471-1479. doi: 10.1007/s00277-018-3301-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/29568990/pubmed" id="29568990" target="_blank">29568990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24638012">
<a name="24638012"></a>Hillmen P, Gribben JG, Follows GA, et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. <i>J Clin Oncol</i>. 2014;32(12):1236-1241. doi:10.1200/JCO.2013.49.6547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/24638012/pubmed" id="24638012" target="_blank">24638012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25882396">
<a name="25882396"></a>Hillmen P, Robak T, Janssens A, et al; COMPLEMENT 1 Study Investigators. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. <i>Lancet.</i> 2015;385(9980):1873-1883. doi:10.1016/S0140-6736(15)60027-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/25882396/pubmed" id="25882396" target="_blank">25882396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18254005">
<a name="18254005"></a>Hodson EM, Willis NS, Craig JC. Non-Corticosteroid Treatment for Nephrotic Syndrome in Children (Review).<i>Cochrane Database Syst Rev</i>. 2010;(4):CD002290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/18254005/pubmed" id="18254005" target="_blank">18254005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23312808">
<a name="23312808"></a>Howman A, Chapman TL, Langdon MM, et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. <i>Lancet</i>. 2013;381(9868):744-751. doi:10.1016/S0140-6736(12)61566-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/23312808/pubmed" id="23312808" target="_blank">23312808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2012">
<a name="KDIGO.2012"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. <i>Kidney Inter</i>. 2012;2:139-274.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7859226">
<a name="7859226"></a>Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. <i>Cancer Treat Rev</i>. 1995;21(1):33-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/7859226/pubmed" id="7859226" target="_blank">7859226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10792277">
<a name="10792277"></a>Kyle RA, Greipp PR, Gertz MA, et al. Waldenström's macroglobulinemia: a prospective study comparing daily with intermittent oral chlorambucil. <i>Br J Haematol</i>. 2000;108(4):737-742.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/10792277/pubmed" id="10792277" target="_blank">10792277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23233721">
<a name="23233721"></a>Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. <i>J Clin Oncol</i>. 2013;31(3):301-307. doi:10.1200/JCO.2012.44.7920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/23233721/pubmed" id="23233721" target="_blank">23233721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26308278">
<a name="26308278"></a>Lepretre S, Dartigeas C, Feugier P, Marty M, Salles G. Systematic review of the recent evidence for the efficacy and safety of chlorambucil in the treatment of B-cell malignancies. <i>Leuk Lymphoma</i>. 2016;57(4):852-865. doi:10.3109/10428194.2015.1085528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/26308278/pubmed" id="26308278" target="_blank">26308278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leukeran.1">
<a name="Leukeran.1"></a>Leukeran (chlorambucil) (prescribing information). Wixom, MI: Waylis Therapeutics LLC; February 2023.</div>
</li>
<li>
<div class="reference">
                  Leukeran (chlorambucil) [product monograph]. Oakville, Ontario, Canada: Aspen Pharmacare Canada Inc; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14531908">
<a name="14531908"></a>Martinelli G, Laszlo D, Bertolini F, et al. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. <i>Br J Haematol</i>. 2003;123(2):271-277. doi:10.1046/j.1365-2141.2003.04586.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/14531908/pubmed" id="14531908" target="_blank">14531908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25047267">
<a name="25047267"></a>Martinelli G, Montoro J, Vanazzi A, et al. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study. <i>Hematol Oncol</i>. 2015;33(4):129-135. doi:10.1002/hon.2154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/25047267/pubmed" id="25047267" target="_blank">25047267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16029446">
<a name="16029446"></a>McMullin MF, Bareford D, Campbell P, et al; General Haematology Task Force of the British Committee for Standards in Haematology. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130(2):174-195. doi:10.1111/j.1365-2141.2005.05535.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/16029446/pubmed" id="16029446" target="_blank">16029446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30426472">
<a name="30426472"></a>McMullin MFF, Mead AJ, Ali S, et al; British Society for Haematology. A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology guideline. <i>Br J Haematol</i>. 2019;184(2):161-175. doi:10.1111/bjh.15647<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/30426472/pubmed" id="30426472" target="_blank">30426472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1739294">
<a name="1739294"></a>Mehregan DA, Winkelmann RK. Necrobiotic xanthogranuloma [published correction appears in <i>Arch Dermatol</i>. 1992;128(5):632]. <i>Arch Dermatol</i>. 1992;128(1):94-100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/1739294/pubmed" id="1739294" target="_blank">1739294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27436448">
<a name="27436448"></a>Miguel D, Lukacs J, Illing T, Elsner P. Treatment of necrobiotic xanthogranuloma - a systematic review. <i>J Eur Acad Dermatol Venereol</i>. 2017;31(2):221-235. doi:10.1111/jdv.13786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/27436448/pubmed" id="27436448" target="_blank">27436448</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nahata MC, Pai VB, Hipple TF. <i>Pediatric Drug Formulations</i>. 5th ed. Cincinnati, OH: Harvey Whitney Books Co; 2004.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11114313">
<a name="11114313"></a>Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. <i>N Engl J Med</i>. 2000;343(24):1750-1757. doi:10.1056/NEJM200012143432402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/11114313/pubmed" id="11114313" target="_blank">11114313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2016618">
<a name="2016618"></a>Raphael B, Andersen JW, Silber R, et al. Comparison of chlorambucil and prednisone versus cyclophosphamide, vincristine, and prednisone as initial treatment for chronic lymphocytic leukemia: long-term follow-up of an Eastern Cooperative Oncology Group randomized clinical trial. <i>J Clin Oncol</i>. 1991;9(5):770-776. doi:10.1200/JCO.1991.9.5.770<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/2016618/pubmed" id="2016618" target="_blank">2016618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12921248">
<a name="12921248"></a>Robinson RF, Nahata MC, Mahan JD. Management of Nephrotic Syndrome in Children. <i>Pharmacotherapy</i>. 2003;23(8):1021-1036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/12921248/pubmed" id="12921248" target="_blank">12921248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22571578">
<a name="22571578"></a>Ryan E, Warren LJ, Szabo F. Necrobiotic xanthogranuloma: response to chlorambucil. <i>Australas J Dermatol</i>. 2012;53(2):e23-e25. doi:10.1111/j.1440-0960.2010.00710.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/22571578/pubmed" id="22571578" target="_blank">22571578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2386744">
<a name="2386744"></a>Selby P, Patel P, Milan S, et al. ChlVPP combination chemotherapy for Hodgkin's disease: long-term results. <i>Br J Cancer</i>. 1990;62(2):279-285. doi:10.1038/bjc.1990.278<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/2386744 /pubmed" id="2386744 " target="_blank">2386744 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15568891">
<a name="15568891"></a>Singh BN, Malhotra BK. Effects of Food on the Clinical Pharmacokinetics of Anticancer Agents: Underlying Mechanisms and Implications for Oral Chemotherapy. <i>Clin Pharmacokinet</i>. 2004;43(15):1127-1156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/15568891/pubmed" id="15568891" target="_blank">15568891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17509875">
<a name="17509875"></a>Stoneham S, Ashley S, Pinkerton R, Hewitt M, Wallace WHP, Shankar AG. Hodgkin’s lymphoma in children aged 5 years or less – the United Kingdom experience. <i>Eur J Cancer</i>. 2007;43:1415-1421.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/17509875/pubmed" id="17509875" target="_blank">17509875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21757618">
<a name="21757618"></a>Szalat R, Arnulf B, Karlin L, et al. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. <i>Blood</i>. 2011;118(14):3777-3784. doi:10.1182/blood-2011-05-356907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/21757618/pubmed" id="21757618" target="_blank">21757618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7786824">
<a name="7786824"></a>The International ChlVPP Treatment Group. ChlVPP Therapy for Hodgkin’s Disease: Experience of 960 Patients. <i>Ann Oncol</i>. 1995;6(2):167-172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/7786824/pubmed" id="7786824" target="_blank">7786824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26242182">
<a name="26242182"></a>Vannucchi AM, Barbui T, Cervantes F, et al; ESMO Guidelines Committee. Philadelphia chromosome–negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2015;26(suppl 5):v85‐v99. doi:10.1093/annonc/mdv203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/26242182/pubmed" id="26242182" target="_blank">26242182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2072145">
<a name="2072145"></a>Vose JM, Bierman PJ, Anderson JR, et al. CHLVPP chemotherapy with involved-field irradiation for Hodgkin’s disease: favorable results with acceptable toxicity. <i>J Clin Oncol</i>. 1991;9(8):1421-1425. doi:10.1200/JCO.1991.9.8.1421<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/2072145/pubmed" id="2072145" target="_blank">2072145</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Wagner AM, Brunet S, Puig J, et al. Chlorambucil-Induced Inappropriate Antidiuresis in Man With Chronic Lymphocytic Leukemia. <i>Ann Hemat</i>. 1999;78(1):37-38.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15527430">
<a name="15527430"></a>Wells J, Gillespie R, Zardawi I. Case of recalcitrant necrobiotic xanthogranuloma. <i>Australas J Dermatol</i>. 2004;45(4):213-215. doi:10.1111/j.1440-0960.2004.00099.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/15527430/pubmed" id="15527430" target="_blank">15527430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-690782">
<a name="690782"></a>Williams SA, Makker SP, Grupe WE. Seizures: A Significant Side Effect of Chlorambucil Therapy in Children. <i>J Pediatr</i>. 1978;93(3):516-518.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/690782/pubmed" id="690782" target="_blank">690782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19289757">
<a name="19289757"></a>Wood AJ, Wagner MV, Abbott JJ, Gibson LE. Necrobiotic xanthogranuloma: a review of 17 cases with emphasis on clinical and pathologic correlation. <i>Arch Dermatol</i>. 2009;145(3):279-284. doi:10.1001/archdermatol.2008.583<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/19289757/pubmed" id="19289757" target="_blank">19289757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28355112">
<a name="28355112"></a>Zucca E, Conconi A, Martinelli G, et al. final results of the ielsg-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. <i>J Clin Oncol</i>. 2017;35(17):1905-1912. doi:10.1200/JCO.2016.70.6994<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlorambucil-pediatric-drug-information/abstract-text/28355112/pubmed" id="28355112" target="_blank">28355112</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13144 Version 247.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
